Skip to Content
Merck
  • Inhibitory effect of phospholipids on P-glycoprotein: cellular studies in Caco-2, MDCKII mdr1 and MDCKII wildtype cells and P-gp ATPase activity measurements.

Inhibitory effect of phospholipids on P-glycoprotein: cellular studies in Caco-2, MDCKII mdr1 and MDCKII wildtype cells and P-gp ATPase activity measurements.

Biochimica et biophysica acta (2012-06-14)
S Simon, R Schubert
ABSTRACT

Phospholipids are widely used excipients for pharmaceutical formulations, such as for preparing biphasic systems or to solubilize or encapsulate poorly soluble drugs. The present study investigates a new property of this class of substance: its ability to inhibit the efflux transporter Pglycoprotein (P-gp). P-gp is expressed in the intestinal epithelium, thereby significantly impairing the systemic absorption of various pharmaceutically active substances. The phospholipid screening performed in this study involved derivatives with different headgroups and fatty acid residues and a number of experimental parameters. For in vitro studies we carried out transport experiments and calcein accumulation assays in Caco-2- and MDCKII mdr1 and wildtype cell lines. The three compounds which displayed significant P-gp inhibition in both assays and in Caco-2 as well as in MDCKII mdr1, consisted of phosphatidylcholine (PC) and either two saturated fatty acid residues of eight (8:0 PC) or ten carbon atoms (10:0 PC), or of two unsaturated docosahexaeonic acid residues (cis-22:6 PC).Supported by P-gp ATPase activity measurements, 8:0 and 10:0 PC were assumed to function as direct P-gp inhibitors interacting with the transporter probably in their monomeric state, whereas a different, as yet unknown mechanism of action applied for cis-22:6 PC.Because of their proven ability to significantly inhibit P-gp in vitro, these phospholipids shall further be elucidated in vivo, whether they may truly serve to increase the bioavailability of orally applied drugs with a P-gp substrate character.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
MDCKII canine MDR1 KO, human BCRP / human OAT2B1 Expressing Cells
Sigma-Aldrich
MDCKII canine MDR1 KO, human BCRP Expressing Cells
Sigma-Aldrich
Canine MDR1 Knockout, Human MDR1 Knockin MDCKII Cells
Sigma-Aldrich
MDCKII canine MDR1 KO, human MDR1 Expressing Cells
Sigma-Aldrich
Canine MDR1 Knockout MDCKII Control Cells
Sigma-Aldrich
MDCKII canine MDR1 KO Cells